These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37934376)

  • 1. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
    Yee CW; Harvey MJ; Xin Y; Kirson NY
    Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
    Song R; Jeet V; Sharma R; Hoyle M; Parkinson B
    Pharmacoeconomics; 2022 Aug; 40(8):807-821. PubMed ID: 35761117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
    Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
    Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
    JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
    Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piflufolastat F-18 (
    Voter AF; Werner RA; Pienta KJ; Gorin MA; Pomper MG; Solnes LB; Rowe SP
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):681-694. PubMed ID: 35603510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory cost-effectiveness analysis of
    Gordon LG; Elliott TM; Joshi A; Williams ED; Vela I
    Clin Exp Metastasis; 2020 Apr; 37(2):305-312. PubMed ID: 32064552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18 F PET/CT in prostate cancer patients in early biochemical failure.
    Maliha PG; Nolet B; Ebrahim A; Abikhzer G; Chaussé G; Bahoric B; Niazi T; Probst S
    Nucl Med Commun; 2023 Mar; 44(3):187-193. PubMed ID: 36525002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of
    Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
    AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
    J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative 18 F-Piflufolastat PET/CT, But Positive 18 F-Fluciclovine PET/CT, in a Patient With Biochemically Recurrent Prostate Cancer.
    Ulaner GA
    Clin Nucl Med; 2024 Oct; 49(10):968-970. PubMed ID: 38693630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence of
    Friedrich NA; Gu L; Waller J; De Hoedt AM; Klaassen Z; Freedland SJ
    Prostate; 2024 Oct; 84(14):1336-1343. PubMed ID: 39031050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
    J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.